An interventional study of The DyaMX Device in Type 2 Diabetes, sponsored by Endogenex, Inc.. Completed at 2 sites in Australia. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-01-22.
Sponsored by Endogenex, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 262 studies in Diabetes Mellitus, Type 2 with a site in Australia — 24 open to participants now, 30 under way, 13 of them phase 3. Diabetes Mellitus, Type 2 · Australia.
Among the 262 studies in Diabetes Mellitus, Type 2 with a site in Australia, this one is the 202nd largest by enrollment of the 246 interventional ones that give a count, is one of 6 that started in 2021, is one of 31 with no phase, and was the 209th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →24 of the 262 studies in Diabetes Mellitus, Type 2 with a site in Australia are open now. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in Australia, United States, Canada and 3 more countries
Ages 18+
AstraZeneca · Sites in Australia, United States, Argentina and 13 more countries
Ages 18+
AstraZeneca · Sites in Australia, United States, Bulgaria and 10 more countries
Ages 18+
AstraZeneca · Sites in Australia, United States, Argentina and 12 more countries
Ages 18+
Novo Nordisk A/S · Sites in Australia, United States, Germany and 6 more countries
Ages 18–75
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
262 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 47 · Phase 3 136 · Phase 4 22
First in 2001; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is below the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 392 across the 246 interventional studies, 911 across the 16 observational. Of the 224 that completed or were terminated, 115 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
223 of 262 have an industry lead sponsor. The 10 most frequent:
Endogenex, Inc. is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
Endogenex, Inc. has 6 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
9 of the studies in Diabetes Mellitus, Type 2 with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06888687Australian Catholic UniversityComparison of Dietetics Support With and Without Continuous Glucose Monitoring in Individuals With Type 2 Diabetes. | 2026-11-28 |
| NCT07228117Medtronic MiniMed, Inc.GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes | 2027-01 |
| NCT06937203Arrowhead PharmaceuticalsA First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus | 2027-02 |
| NCT06267391Endogenex, Inc.Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes | 2027-02-01 |
| NCT07215559Eli Lilly and CompanyA Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes | 2027-03 |
Add all 9 to your calendar (.ics) → With an account.
Among the 262 studies in Diabetes Mellitus, Type 2 with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label study to assess the safety and feasibility of the DyaMX device for endoscopic duodenal mucosal regeneration in individuals with type 2 diabetes inadequately controlled on glucose-lowering medications.
Individuals who sign the informed consent will be screened for study eligibility. Eligible participants will be treated with the DyaMX procedure and followed up for 48 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Critically ill or has a \<3 years
Additional exclusion criteria to be confirmed during the screening process:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All eligible participants will receive the DyaMX procedure.
Device: The DyaMX Device
The DyaMX device is designed to induce duodenal mucosal regeneration using pulsed electric field. The DyaMX procedure is a non-surgical, endoscopic procedure.
Also known as: Duodenal Mucosal Regeneration
Number of Participants With Device- or Procedure-related Serious Adverse Events (SAE)
Number of participants experiencing one or more device- or procedure-related serious adverse events at 12 weeks post procedure
Time frame: At 12 weeks post procedure
HbA1c by Post Procedure Follow-up Visit
Mean HbA1c (%) by Post Procedure Follow-up Visit. The unit of measure for HbA1c is %.
Time frame: Follow up at 12, 24, and 48 weeks post procedure
Fasting Plasma Glucose by Visit
Mean Fasting Plasma Glucose by Visit
Time frame: Baseline, 12, 24, and 48 weeks
Weight by Visit
Mean Weight by Visit
Time frame: Baseline, 12, 24, and 48 weeks
Procedural Success
Percentage of participants with successful DMR procedure
Time frame: At the time of the Index Procedure
Procedural Time
Time between catheter insertion to catheter removal
Time frame: Time of Procedure
Participants were recruited from 3 medical centers in Australia between January of 2021 and November of 2023. Participants were considered enrolled in the study once they passed endoscopic screening. Screen failures were defined as participants who consented for the study, started the screening process but were not subsequently enrolled. The first participant was enrolled on 20-Apr-2021 and the last on 27-Jul-2023.
| Milestone | Intervention- Endogenex (PEF) Treatment |
|---|---|
| Started | 65 |
| Completed | 59 |
| Not completed | 6 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Physician decision | 1 |
Number of participants experiencing one or more device- or procedure-related serious adverse events at 12 weeks post procedure
| Participants | Intervention- Non-Insulin Cohort | Intervention- Insulin Cohort |
|---|---|---|
| Number of Participants With Device- or Procedure-related Serious Adverse Events (SAE) | 0 | 1 |
Mean HbA1c (%) by Post Procedure Follow-up Visit. The unit of measure for HbA1c is %.
| HbA1c % | Intervention- Non-Insulin Cohort | Intervention- Insulin Cohort |
|---|---|---|
| Mean HbA1c at Baseline | 8.8 ± 0.9 | 8.5 ± 0.8 |
| Mean HbA1c at 12 Weeks | 7.7 ± 1.2 | 7.9 ± 0.99 |
| Mean HbA1c at 24 Weeks | 7.8 ± 2.4 | 8.1 ± 1.0 |
| Mean HbA1c at 48 Weeks | 7.7 ± 2.4 | 7.6 ± 1.0 |
Mean Fasting Plasma Glucose by Visit
| mmol/L | Intervention- Non-Insulin Cohort | Intervention- Insulin Cohort |
|---|---|---|
| Mean FPG at Baseline | 10.1 ± 2.7 | 8.6 ± 1.6 |
| Mean FPG at 12 Weeks | 8.4 ± 2.3 | 8.3 ± 2.3 |
| Mean FPG at 24 Weeks | 7.6 ± 2.6 | 8.8 ± 2.9 |
| Mean FPG at 48 Weeks | 7.9 ± 3.1 | 7.5 ± 1.9 |
Mean Weight by Visit
| kg | Intervention- Non-Insulin Cohort | Intervention- Insulin Cohort |
|---|---|---|
| Mean Weight at Baseline | 94 ± 15 | 80 ± 12 |
| Mean Weight at 12 Weeks | 90 ± 14 | 79 ± 11 |
| Mean Weight at 24 Weeks | 86 ± 32 | 77 ± 12 |
| Mean Weight at 48 Weeks | 89 ± 30 | 73 ± 12 |
Percentage of participants with successful DMR procedure
| Participants | Intervention- Non-Insulin Cohort | Intervention- Insulin Cohort |
|---|---|---|
| Procedural Success | 51 | 14 |
Time between catheter insertion to catheter removal
| Minutes | Intervention- Non-Insulin Cohort | Intervention- Insulin Cohort |
|---|---|---|
| Procedural Time | 74.3 ± 31.7 | 102.5 ± 36.5 |
Collected over Baseline through 48 Weeks (duration of the study). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intervention- Endogenex (PEF) Treatment | 0/65 (0%) | 5/65 (7.7%) | 58/65 (89.2%) |
| Event | Intervention- Endogenex (PEF) Treatment |
|---|---|
| Colon CancerGastrointestinal disorders | 1/65 |
| Cerebrovascular AccidentNervous system disorders | 1/65 |
| Myocardial ischemiaCardiac disorders | 1/65 |
| PyrexiaGeneral disorders | 1/65 |
| TonsillitisInfections and infestations | 1/65 |
| Celiac Artery stenosisGastrointestinal disorders | 1/65 |
| PancreatitisGastrointestinal disorders | 1/65 |
| Event | Intervention- Endogenex (PEF) Treatment |
|---|---|
| COVID-19Infections and infestations | 26/65 |
| Oropharyngeal painGastrointestinal disorders | 26/65 |
| DiarrheaGastrointestinal disorders | 15/65 |
| NauseaGastrointestinal disorders | 7/65 |
| ConstipationGastrointestinal disorders | 6/65 |
| Gastroesophageal reflux diseaseGastrointestinal disorders | 5/65 |
| Adverse Drug ReactionGeneral disorders | 4/65 |
| Abdominal painGastrointestinal disorders | 3/65 |
| Back painMusculoskeletal and connective tissue disorders | 3/65 |
| FlatulenceGastrointestinal disorders | 3/65 |
| Age, Continuous(years) | Intervention- Non-Insulin Cohort | Intervention- Insulin Cohort | Total |
|---|---|---|---|
| Mean | 52.8 ± 8.0 | 58.1 ± 7.0 | 53.9 ± 8.0 |
| Sex: Female, Male(Participants) | Intervention- Non-Insulin Cohort | Intervention- Insulin Cohort | Total |
|---|---|---|---|
| Female | 13 | 8 | 21 |
| Male | 38 | 6 | 44 |
| Ethnicity (NIH/OMB)(Participants) | Intervention- Non-Insulin Cohort | Intervention- Insulin Cohort | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 2 |
| Not Hispanic or Latino | 49 | 14 | 63 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Intervention- Non-Insulin Cohort | Intervention- Insulin Cohort | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 11 | 2 | 13 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 0 | 1 | 1 |
| White | 35 | 6 | 41 |
| More than one race | 4 | 5 | 9 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Intervention- Non-Insulin Cohort | Intervention- Insulin Cohort | Total |
|---|---|---|---|
| Australia | 51 | 14 | 65 |
| HbA1c(%) | Intervention- Non-Insulin Cohort | Intervention- Insulin Cohort | Total |
|---|---|---|---|
| Mean | 8.8 ± 0.9 | 8.5 ± 0.8 | 8.7 ± 0.9 |
| Weight(Kg) | Intervention- Non-Insulin Cohort | Intervention- Insulin Cohort | Total |
|---|---|---|---|
| Mean | 93.6 ± 15.4 | 80.2 ± 11.8 | 90.7 ± 15.6 |
| BMI (kg/m^2)(kg/m^2) | Intervention- Non-Insulin Cohort | Intervention- Insulin Cohort | Total |
|---|---|---|---|
| Mean | 31.5 ± 3.5 | 29.5 ± 4.2 | 31.1 ± 3.7 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2021 to primary completion in Mar 2024, 34 months.
Results were first posted in Jan 2026, 1 year 10 months after primary completion.
Of 177 industry-sponsored interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 29. This study's 34 months is above that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Endogenex, Inc.